American Research & Management Co. trimmed its holdings in shares of Novartis AG (NYSE:NVS) by 1.7% in the 1st quarter, HoldingsChannel.com reports. The fund owned 55,469 shares of the company’s stock after selling 962 shares during the quarter. Novartis comprises approximately 1.1% of American Research & Management Co.’s holdings, making the stock its 29th largest holding. American Research & Management Co.’s holdings in Novartis were worth $4,741,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Confluence Investment Management LLC boosted its stake in shares of Novartis by 1.5% during the 1st quarter. Confluence Investment Management LLC now owns 250,831 shares of the company’s stock worth $21,441,000 after acquiring an additional 3,707 shares in the last quarter. Fulton Bank N.A. increased its holdings in Novartis by 30.6% in the 1st quarter. Fulton Bank N.A. now owns 13,473 shares of the company’s stock worth $1,152,000 after acquiring an additional 3,160 shares in the last quarter. Thomasville National Bank raised its position in Novartis by 28.9% during the first quarter. Thomasville National Bank now owns 8,475 shares of the company’s stock worth $699,000 after acquiring an additional 1,900 shares during the period. Bard Financial Services Inc. purchased a new position in Novartis in the 4th quarter valued at about $631,000. Finally, Curi Capital acquired a new position in shares of Novartis during the fourth quarter valued at approximately $61,000. Institutional investors and hedge funds own 9.86% of the company’s stock.
Shares of Novartis stock traded up $0.79 on Thursday, reaching $87.09. The company had a trading volume of 72,577 shares, compared to its average volume of 1,990,229. The firm’s 50 day moving average price is $86.31 and its two-hundred day moving average price is $88.58. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.69 and a current ratio of 0.91. Novartis AG has a 52-week low of $77.04 and a 52-week high of $98.52. The firm has a market cap of $199.32 billion, a PE ratio of 27.93, a PEG ratio of 1.76 and a beta of 0.59.
The company also recently disclosed an annual dividend, which was paid on Monday, March 15th. Stockholders of record on Friday, March 5th were paid a $3.3784 dividend. The ex-dividend date of this dividend was Thursday, March 4th. This is a boost from Novartis’s previous annual dividend of $3.04. This represents a dividend yield of 2.2%. Novartis’s payout ratio is presently 39.69%.
Several equities research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft started coverage on shares of Novartis in a research note on Friday, January 15th. They set a “buy” rating on the stock. Sanford C. Bernstein began coverage on Novartis in a research report on Monday, March 22nd. They set a “market perform” rating on the stock. Societe Generale reissued a “buy” rating on shares of Novartis in a report on Tuesday, March 23rd. Cowen downgraded shares of Novartis from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $110.00 to $105.00 in a research note on Monday, February 1st. Finally, Barclays restated an “underweight” rating on shares of Novartis in a report on Friday, January 22nd. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $108.50.
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products.
Read More: What is an overbought condition?
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.